Immunotherapy最新文献

Dupilumab improves symptoms and quality of life in patients with eosinophilic esophagitis: a plain language summary. Dupilumab改善嗜酸性粒细胞性食管炎患者的症状和生活质量：简单的语言总结

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-07 DOI: 10.1080/1750743X.2026.2658371

Mary Jo Strobel, Jonathan M Spergel, Mirna Chehade, Evan S Dellon, Albert J Bredenoord, Bram P Raphael, Cristina Almansa, Sarette T Tilton, Ryan B Thomas

引用次数: 0

Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager. 塔拉他单抗治疗复发性小细胞肺癌：一种dll3靶向双特异性t细胞结合剂。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-04 DOI: 10.1080/1750743X.2026.2668210

Prodromos Koutoukoglou, Giannis Mountzios

{"title":"Tarlatamab in relapsed small-cell lung cancer: a DLL3-targeted bispecific T-cell engager.","authors":"Prodromos Koutoukoglou, Giannis Mountzios","doi":"10.1080/1750743X.2026.2668210","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2668210","url":null,"abstract":"Relapsed small cell lung cancer (SCLC) is widely considered as a difficult-to-treat disease with an adverse prognosis and scarce therapeutic options, especially in the case of platinum-resistance. Tarlatamab (IMDELLTRA™), a first-in-class, Delta-like ligand-3 (DLL3)-targeted bispecific T-cell engager (BiTE), works by creating a molecular bridge between DLL3 on tumor cells and CD3 on T-cells, leading to T-cell activation and Τ-cell-mediated tumor cell lysis. Tarlatamab demonstrated promising efficacy in early-phase trials at the cost of immune-mediated toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS and ICANS emerge primarily during the first two cycles of treatment, have low to moderate severity and are generally manageable with general supportive measures and specialized immunosuppressive treatment including corticosteroids and monoclonal antibodies like tocilizumab. Tarlatamab appears to be a promising choice for relapsed SCLC, based on the results of the Phase III DeLLphi-304 trial, which demonstrated a clinically and statistically meaningful improvement in overall survival (OS) with its use compared to approved second-line chemotherapy (ChT) options. Having been recently granted FDA approval for use in patients with SCLC who progressed on or after platinum-based ChT, tarlatamab is currently being evaluated in multiple settings of SCLC, including first-line and maintenance treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.3,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy. 下一代癌症免疫疗法：CAR - t细胞疗法的前景。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-04 DOI: 10.1080/1750743X.2026.2668205

Harshad S Kapare, Rutuja Jadhav, Pawan N Karwa, Ritesh P Bhole, Sonali Labhade

{"title":"Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy.","authors":"Harshad S Kapare, Rutuja Jadhav, Pawan N Karwa, Ritesh P Bhole, Sonali Labhade","doi":"10.1080/1750743X.2026.2668205","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2668205","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell treatment has developed among major substantial improvements for modern cancer treatment, providing sustained responses in patients with otherwise resistant blood cancers. This method comprises of patients reprogramming or donor's T lymphocytes to interpret tumor associated antigens self-sufficiently of major histocompatibility multifaceted presentation, thereby circumventing a key limitation of natural immune surveillance. The approval of CD19- and BCMA-targeted therapies demonstrated remarkable clinical impact and validated the approach. Over successive generations, CAR constructs have been refined with additional costimulatory elements, cytokine support, and multifunctional signaling domains, improving both their persistence and therapeutic activity. Despite such progress, important challenges remain, including risks of relapse, toxicity including neurotoxicity and cytokine release syndrome with limited efficacy in solid tumors. Current research is focused on strategies, such as armored CARs, gene editing, and combination therapies to expand clinical benefit. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases, covering publications from 2000 to 2026 till date. Relevant peer-reviewed articles were selected based on their relevance to CAR T-cell therapy, including preclinical and clinical studies. Detailed search strategy, inclusion criteria, and screening methods are described in the main manuscript. This review explores the evolution, applications, and future outlook of CAR T-cell rehabilitation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-22"},"PeriodicalIF":2.3,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ELAVL1 increases macrophage M1 polarization via upregulating S100A8 to promote Crohn's disease progression. ELAVL1通过上调S100A8增加巨噬细胞M1极化，促进克罗恩病进展。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-05-03 DOI: 10.1080/1750743X.2026.2662145

Lin Jia, Yingtai Chen, Ying Lu

{"title":"ELAVL1 increases macrophage M1 polarization via upregulating S100A8 to promote Crohn's disease progression.","authors":"Lin Jia, Yingtai Chen, Ying Lu","doi":"10.1080/1750743X.2026.2662145","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2662145","url":null,"abstract":"Objective: This study aims to investigate the impact and molecular mechanism of ELAVL1 in promoting macrophage M1 polarization in Crohn's disease (CD) by upregulating S100A8 expression.Methods: Peripheral blood mononuclear cells (PBMCs) from CD patients were collected to assess the expression of S100A8 and ELAVL1. The effect of ELAVL1/S100A8 on THP1 derived macrophage polarization and pro-inflammatory mediator secretion were evaluated via siRNA silencing and rescue experiments. RNA-binding protein immunoprecipitation (RIP) and RNA pull-down assays validated the interaction between ELAVL1 and S100A8.Results: Both S100A8 and ELAVL1 were significantly overexpressed in CD patients. Knockdown of S100A8 or ELAVL1 in M1-polarized macrophages marked reduced the expression of M1 biomarkers (CD80, CD86) and pro-inflammatory mediators. However, S100A8 overexpression reversed the inhibitory effects of ELAVL1 knockdown on M1 polarization, thereby promoting the M1 polarization and inflammatory response. RIP and RNA pull-down assays confirmed that ELAVL1 directly binds to S100A8 mRNA to regulate its expression.Conclusion: ELAVL1 promotes M1 polarization of macrophages to exacerbate intestinal inflammation in CD via up-regulating S100A8 expression. These findings highlight the ELAVL1/S100A8 axis as a potential therapeutic target or diagnostic biomarker for managing CD.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.3,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could immunotherapy be a feasible treatment option for patient's suffering from chronic epilepsy? 免疫疗法能否成为慢性癫痫患者的可行治疗选择？

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-29 DOI: 10.1080/1750743X.2026.2665027

Colin P Doherty

引用次数: 0

Correction. 修正。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-28 DOI: 10.1080/1750743X.2026.2665946

引用次数: 0

Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials. Pembrolizumab联合化疗治疗PD-L1低表达晚期或转移性非小细胞肺癌：随机对照试验的系统回顾和荟萃分析

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-27 DOI: 10.1080/1750743X.2026.2665031

Akhil Deepak Vatvani, Gilbert Lazarus, Reyad Al Jabiri, Rama Nada, Maria Albuja Altamirano, Eunhee Choi, Nehad Shabarek

{"title":"Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials.","authors":"Akhil Deepak Vatvani, Gilbert Lazarus, Reyad Al Jabiri, Rama Nada, Maria Albuja Altamirano, Eunhee Choi, Nehad Shabarek","doi":"10.1080/1750743X.2026.2665031","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2665031","url":null,"abstract":"Introduction: Pembrolizumab plus chemotherapy is widely used as first-line treatment for advanced NSCLC, but its benefit in patients with low PD-L1 expression remains uncertain. This study evaluated pembrolizumab plus chemotherapy versus chemotherapy alone in advanced or metastatic NSCLC with PD-L1 <50%.Methods: PubMed, Scopus, and Cochrane databases were searched for randomized controlled trials up to 17 September 2025. Primary outcomes were overall survival (OS) and progression-free survival (PFS).Results: Four randomized controlled trials (n = 2,413) were included. Pembrolizumab plus chemotherapy improved overall survival (HR 0.67, 95% CI 0.46-0.96), while progression-free survival showed a non-significant trend (HR 0.66, 95% CI 0.42-1.03). Subgroup analyses by PD-L1 (<1% and 1-49%) showed borderline, non-significant effects. Objective response rate was higher overall (RR 1.75, 95% CI 1.13-2.70) but not significant by subgroup, with moderate heterogeneity. Certainty of evidence was low. Safety outcomes were not pooled; available data suggested similar adverse events but higher immune-related toxicity and numerically higher treatment-related deaths.Conclusions: Pembrolizumab plus chemotherapy may improve survival in advanced NSCLC with low PD-L1 expression, but benefits were inconsistent across subgroups and limited by imprecision and heterogeneity. Safety data remain limited and should be interpreted cautiously.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis. 转移性非小细胞肺癌一线治疗加化疗：基于中国的成本-效果分析

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-24 DOI: 10.1080/1750743X.2026.2660567

Zixuan Zhang, Kehui Meng, Meiyu Wu, Andong Li, Yangke Yi, Chaohao Shi, Xiaomin Wan, Chongqing Tan, Zhongbiao Jiang

{"title":"First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis.","authors":"Zixuan Zhang, Kehui Meng, Meiyu Wu, Andong Li, Yangke Yi, Chaohao Shi, Xiaomin Wan, Chongqing Tan, Zhongbiao Jiang","doi":"10.1080/1750743X.2026.2660567","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2660567","url":null,"abstract":"Objective: To assess the cost-effectiveness of sugemalimab plus chemotherapy as first-line treatment for metastatic Non-small cell lung cancer(NSCLC) in China.Methods: A three-state Markov model with 21-day cycles over 10 years was developed to compare sugemalimab plus chemotherapy versus placebo plus chemotherapy. Key model inputs were derived from the 4-year survival data of the GEMSTONE-302 trial and publicly available sources. Outcomes were measured in quality-adjusted life years(QALYs) and incremental cost-effectiveness ratios(ICERs). The willingness-to-pay(WTP) threshold was set at three times the per capita GDP of China in 2024(40,062.34$/QALY). Sensitivity analyses were performed to assess model robustness.Results: Base-case ICERs were 65,766.82$/QALY for squamous and 70,117.72$/QALY for non-squamous NSCLC, both above the WTP threshold. Subgroup analyses indicated that patients with PD-L1 expression ≥50% had the most favorable ICER(60,516.14$/QALY), while those with PD-L1 < 1% had the least favorable outcome(80,599.12$/QALY). Sensitivity analyses identified drug price and utility values as the most influential parameters affecting ICERs.Conclusion: Sugemalimab plus platinum-based chemotherapy offers long-term clinical benefits for metastatic NSCLC but is not cost-effective at current prices in China. Improving cost-effectiveness may require targeting patients with high PD-L1 expression, adjusting reimbursement policies, and reducing drug prices.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.3,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions. 免疫检查点抑制剂在POLE/POLD1校对缺陷CRC中的应用：从分子基础到临床实践和未来方向

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-22 DOI: 10.1080/1750743X.2026.2662823

Lei Jiang, Zhongxia Yang, Xiaojun Liu

{"title":"Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.","authors":"Lei Jiang, Zhongxia Yang, Xiaojun Liu","doi":"10.1080/1750743X.2026.2662823","DOIUrl":"https://doi.org/10.1080/1750743X.2026.2662823","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have fundamentally reshaped the therapeutic paradigm for metastatic colorectal cancer (mCRC). Beyond the established dMMR/MSI-H population, a molecularly distinct, hyper-immunogenic subset-governed by pathogenic aberrations in the exonuclease domains of POLE/POLD1-has emerged as a pivotal clinical entity. Characterized by an ultra-hypermutated phenotype, these tumors harbor a mutational load that typically dwarfs the benchmarks established by dMMR/MSI-H malignancies. In this review, we synthesize the molecular underpinnings of POLE/POLD1 deficiency, emphasizing a \"threshold effect\" where extreme neoantigen density triggers a self-reinforcing inflammatory loop, fundamentally reshaping the tumor immune microenvironment (TIME). To ensure a robust synthesis of the field, a systematic literature search was conducted using the PubMed and Web of Science databases until December 2025, with additional manual screening of reference lists from key studies. Our analysis underscores superior, often durable, responses in this subgroup, while addressing a formidable obstacle: the interpretation of Variants of Uncertain Significance (VUS). We highlight the critical need to distinguish passenger mutations from true proofreading defects, as therapeutic benefit is strictly tethered to functional pathogenicity. Finally, we propose an integrated biomarker framework that moves beyond binary genomic screening toward a functional hierarchy of polymerase variants, providing a definitive roadmap for the next generation of precision immunotherapy in colorectal cancer.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-04-21 DOI: 10.1080/1750743X.2026.2662201

Ali Kaan Güren, Nazım Can Demircan, Özge Gümüşay, Eda Tanrıkulu Şimşek, Fatih Kemik, Çağla Karaoğlu, Taha Koray Şahin, Salih Tünbekici, Kübra Akkaya, Murad Guliyev, Barış Gezici, Hasibe Bilge Gür, Delyadil Karakaş, Ahmet Ünlü, Oğuz Altunok, İsmail Nazlı, Sedat Biter, Tuğba Kaya, Özge Yetginoğlu, Tuğçe Kübra Güneş, Lamia Şeker Can, Nargiz Majidova, Nadiye Sever, Aysun Fatma Akkuş, İsmail Oğuz Kara, Banu Öztürk, Adem Deligönül, Muhammet Ali Kaplan, Elif Atağ, İlhan Hacıbekiroğlu, Nebi Serkan Demirci, Fatih Selçuk Biricik, Deniz Can Güven, Sercan Aksoy, Rukiye Arıkan, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek

{"title":"Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.","authors":"Ali Kaan Güren, Nazım Can Demircan, Özge Gümüşay, Eda Tanrıkulu Şimşek, Fatih Kemik, Çağla Karaoğlu, Taha Koray Şahin, Salih Tünbekici, Kübra Akkaya, Murad Guliyev, Barış Gezici, Hasibe Bilge Gür, Delyadil Karakaş, Ahmet Ünlü, Oğuz Altunok, İsmail Nazlı, Sedat Biter, Tuğba Kaya, Özge Yetginoğlu, Tuğçe Kübra Güneş, Lamia Şeker Can, Nargiz Majidova, Nadiye Sever, Aysun Fatma Akkuş, İsmail Oğuz Kara, Banu Öztürk, Adem Deligönül, Muhammet Ali Kaplan, Elif Atağ, İlhan Hacıbekiroğlu, Nebi Serkan Demirci, Fatih Selçuk Biricik, Deniz Can Güven, Sercan Aksoy, Rukiye Arıkan, Murat Sarı, İbrahim Vedat Bayoğlu, Osman Köstek","doi":"10.1080/1750743X.2026.2662201","DOIUrl":"10.1080/1750743X.2026.2662201","url":null,"abstract":"Purpose: Neoadjuvant chemoimmunotherapy improved pathological complete response (pCR) rates in early triple-negative breast cancer (TNBC). However, the relationship between immune-related adverse events (irAEs) and treatment response remains unclear. This study evaluated the association between the development of irAEs and pCR in TNBC patients receiving neoadjuvant pembrolizumab-based therapy.Method: In this multicenter retrospective study, early TNBC patients who received neoadjuvant pembrolizumab-based therapy were evaluated. Clinicopathologic features, irAE occurrence, and pCR rates were recorded and analyzed.Results: Among 203 patients who completed neoadjuvant treatment and underwent surgery, 127 (62.6%) achieved pCR. irAEs were more frequent in the pCR group compared with the non-pCR group (35.4% vs 19.7%, respectively; p = 0.01). Both univariate and multivariate analyses confirmed a significant association between irAE development and pCR.Conclusion: In patients with early TNBC treated with neoadjuvant pembrolizumab, irAEs occurred more often in those achieving pCR. These findings suggest that irAEs may reflect enhanced immune activation and could serve as a potential indicator of treatment response. Further prospective studies are needed to validate this observation and clarify its clinical relevance.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0